Clinical Trials Directory

Trials / Completed

CompletedNCT02277574

Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis

A Randomized, Multi-Dose, Placebo-Controlled, Study of the Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
29 (actual)
Sponsor
MedImmune LLC · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This is a Phase 1b, randomized, multi-dose, placebo-controlled, dose-escalation, multi-center study of AMP-110 in adult subjects with rheumatoid arthritis.

Conditions

Interventions

TypeNameDescription
BIOLOGICALAMP-1102, 5, or 10 mg/kg
OTHERPlaceboPlacebo

Timeline

Start date
2014-06-01
Primary completion
2015-01-01
Completion
2015-07-01
First posted
2014-10-29
Last updated
2016-11-21

Locations

7 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02277574. Inclusion in this directory is not an endorsement.